GB0800702D0 - Genes - Google Patents

Genes

Info

Publication number
GB0800702D0
GB0800702D0 GB0800702A GB0800702A GB0800702D0 GB 0800702 D0 GB0800702 D0 GB 0800702D0 GB 0800702 A GB0800702 A GB 0800702A GB 0800702 A GB0800702 A GB 0800702A GB 0800702 D0 GB0800702 D0 GB 0800702D0
Authority
GB
United Kingdom
Prior art keywords
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB0800702A
Other versions
GB2456390A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0800702A priority Critical patent/GB2456390A/en
Publication of GB0800702D0 publication Critical patent/GB0800702D0/en
Publication of GB2456390A publication Critical patent/GB2456390A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
GB0800702A 2008-01-15 2008-01-15 Bipolar disorder treatments Pending GB2456390A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0800702A GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0800702A GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Publications (2)

Publication Number Publication Date
GB0800702D0 true GB0800702D0 (en) 2008-02-20
GB2456390A GB2456390A (en) 2009-07-22

Family

ID=39144965

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0800702A Pending GB2456390A (en) 2008-01-15 2008-01-15 Bipolar disorder treatments

Country Status (1)

Country Link
GB (1) GB2456390A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110172507A (en) * 2019-06-11 2019-08-27 中国人民解放军第四军医大学 A kind of Large Vestibular Aqueduct/Pendred syndrome Disease-causing gene SLC26A4 abrupt climatic change kit
CN110272992A (en) * 2019-06-27 2019-09-24 郑湘榕 Reagent, kit and the application of the detection of childhood asthma disease are used for based on the site gene rs37972 GLCCI1
CN114236123A (en) * 2021-12-13 2022-03-25 深圳华大基因股份有限公司 Application of marker in predicting gestational diabetes risk
CN114236123B (en) * 2021-12-13 2024-04-19 深圳华大基因股份有限公司 Application of marker in predicting gestational diabetes risk

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986370B2 (en) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Uses of RGM and its modulators
JP2009510002A (en) 2005-09-30 2009-03-12 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Binding domains of proteins of the repulsion-inducing molecule (RGM) protein family, and functional fragments thereof, and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2510001B1 (en) 2009-12-08 2015-12-02 AbbVie Deutschland GmbH & Co KG Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
PL2807192T3 (en) 2012-01-27 2019-02-28 Abbvie Deutschland Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CA3103385A1 (en) 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
CN111172274B (en) * 2020-01-22 2021-10-15 清华大学 Application of Synaptotagmin-7 in diagnosis and treatment of bidirectional affective disorder

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412515A2 (en) * 2001-01-16 2004-04-28 Genset Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
WO2006081350A2 (en) * 2005-01-26 2006-08-03 Rutgers, The State University Of New Jersey Methods and compositions for the diagnosis and treatment of schizophrenia
JP2009536022A (en) * 2006-04-19 2009-10-08 ジェネンテック・インコーポレーテッド Novel gene disruption and related compositions and methods

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110172507A (en) * 2019-06-11 2019-08-27 中国人民解放军第四军医大学 A kind of Large Vestibular Aqueduct/Pendred syndrome Disease-causing gene SLC26A4 abrupt climatic change kit
CN110272992A (en) * 2019-06-27 2019-09-24 郑湘榕 Reagent, kit and the application of the detection of childhood asthma disease are used for based on the site gene rs37972 GLCCI1
CN114236123A (en) * 2021-12-13 2022-03-25 深圳华大基因股份有限公司 Application of marker in predicting gestational diabetes risk
CN114236123B (en) * 2021-12-13 2024-04-19 深圳华大基因股份有限公司 Application of marker in predicting gestational diabetes risk

Also Published As

Publication number Publication date
GB2456390A (en) 2009-07-22

Similar Documents

Publication Publication Date Title
EP2280616A4 (en) Babybody
GB0800702D0 (en) Genes
EP2257170A4 (en) Tetrahydrofuropyridones
EP2285758A4 (en) Fertilizer-pesticide throw-pack
EP2313147A4 (en) Morselizer
EP2328404A4 (en) Resistance genes
GB0801600D0 (en) Microtrench
EP2233305A4 (en) Printer-plotter
EP2285375A4 (en) Spiroazaindoles
GB0801589D0 (en) Mollusicide
GB0800389D0 (en) Gileo hang-it
GB0800161D0 (en) Rota-board
GB0811149D0 (en) Gene
AU3935P (en) DPV308 Dianella prunina
AU3977P (en) PARV01 Myoporum parvifolium
AU4098P (en) NPW2 Dianella tasmanica
AU3972P (en) Tobruk xTriticosecale
GB0805738D0 (en) Genes 01
GB0914134D0 (en) Novel genes
GB0800104D0 (en) Dissolve-a-bottle
GB0800902D0 (en) Gumtray
GB0800481D0 (en) Mum-brella
AU323550S (en) Sidechair
GB0800531D0 (en) Webcanvas
AU2008315V (en) DT5001 Dianella tasmanica